Stratec (SBS) Q3 2025 earnings summary

Executive summary

• Sales grew 2.5% year-over-year at constant currency to EUR 175.6 million, despite supply chain disruptions, volatile customer orders, and trade policy tensions.

• Margin development was negatively impacted by unfavorable product mix and foreign exchange headwinds, though efficiency measures are beginning to support stabilization.

• Market stabilization observed, with end-customer demand and testing volumes recovering, especially in immunoassay and complex sample prep, though molecular test volumes remain below pre-pandemic levels.

• New partnerships and development activities increased, with double-digit growth in Development and Services sales and a major new program in molecular diagnostics.

• Efficiency measures and a focus on high-margin development sales are expected to drive improved earnings in Q4 2025.

Financial highlights

• Adjusted EBIT margin for the first nine months was 7.3%, down from 8.8% year-over-year, mainly due to lower gross margin and product mix.

• Adjusted net income decreased by 15.8% year-over-year to EUR 7.1 million; adjusted EPS was EUR 0.58.

• Adjusted EBITDA for 9M 2025 was EUR 24.2 million, down 9.0% year-over-year; adjusted EBITDA margin was 13.8%, down 160 bps.

• Gross margin declined from 27.4% to 25.8% year-over-year, impacted by product mix and FX rates.

• Free cash flow was negative at -EUR 14.8 million, with cash at period end at EUR 22.4 million, down from EUR 47.2 million at the start of the year.

Outlook and guidance

• Full-year 2025 sales expected to be flat year-over-year at constant currency, with adjusted EBIT margin forecasted at 10%-12%, likely at the lower end.

• Q4 earnings expected to improve significantly due to a better regional mix, higher-margin development and service sales, and lower tax rate.

• Investment in tangible and intangible assets for the year expected to be slightly below the 8%-10% of sales range.

• Cost discipline, efficiency measures, and inventory reduction remain focus areas, alongside growth investments and M&A pipeline management.